Literature DB >> 2786435

Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma.

M Kawano1, H Tanaka, H Ishikawa, M Nobuyoshi, K Iwato, H Asaoku, O Tanabe, A Kuramoto.   

Abstract

Recombinant interleukin 1 alpha (rIL-1 alpha) augmented proliferation of freshly isolated myeloma cells as well as B-cell stimulatory factor 2 (BSF-2)/interleukin-6 (IL-6). Recombinant IL-1 alpha-induced proliferation was partially inhibited by anti-IL-6 antibody. In the culture supernatants of rIL-1 alpha-stimulated myeloma cells, IL-6 activities, which were measured by using an IL-6-dependent murine hybridoma clone, MH60.BSF2, were increased, when compared with those in the culture supernatants of nonstimulated myeloma cells. Furthermore, IL-6 messenger RNA (mRNA) expression was also augmented in IL-1 alpha-stimulated myeloma cells. Therefore rIL-1 alpha stimulates myeloma cells to produce IL-6, which consequently augments proliferation of myeloma cells. Thus, IL-1 can accelerate autocrine growth of myeloma cells through IL-6.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786435

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

2.  Secretory IgA in saliva can be a useful stress marker.

Authors:  S Tsujita; K Morimoto
Journal:  Environ Health Prev Med       Date:  1999-04       Impact factor: 3.674

Review 3.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Gene expression of cytokines suppressing hematopoietic progenitor cells in lymphoid malignancies.

Authors:  C Kawasaki; S Okamura; S Hayashi; S Kondo; M Harada; Y Niho
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

6.  A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.

Authors:  E J Ahsmann; R J Benschop; T D de Gruyl; J A Faber; H M Lokhorst; A C Bloem
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 7.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

8.  Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor).

Authors:  Joanne P Lagmay; Wendy B London; Thomas G Gross; Amanda Termuhlen; Nicholas Sullivan; Amy Axel; Bethany Mundy; Mark Ranalli; Jason Canner; Patrick McGrady; Brett Hall
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop.

Authors:  R Burger; J Wendler; K Antoni; G Helm; J R Kalden; M Gramatzki
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.